Funding for this research was provided by:
National Institute on Aging (NS090934, AG047644)
National Institutes of Health (MH110550)
JPB Foundation (NA)
Appel Alzheimer's disease Research institute (NA)
Washington University–Centene Personalize Medicine Initiative (NA)
Received: 26 February 2020
Accepted: 8 June 2020
First Online: 17 June 2020
Ethics approval and consent to participate
: All experiments were conducted in accordance with relevant NIH guidelines and regulations related to the Care and Use of Laboratory Animals and human tissue. Animal procedures were performed according to protocols approved by the Research Animal Resource Center at Weill Cornell Medicine.
: Not applicable.
: S.M. Paul is a founder, board member, and shareholder of Sage Therapeutics and Voyager Therapeutics. He’s also CEO, board member and shareholder of Karuna Therapeutics and a board member and shareholder of Alnylam Pharmaceuticals as well as a venture partner at Third Rock Ventures. D.F. Covey is a founder and shareholder in Sage Therapeutics. J Doherty and M Lewis are employees and shareholders of Sage Therapeutics. D.M. Holtzman is listed as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M. Holtzman co-founded and is on the scientific advisory board of C2N Diagnostics, LLC. C2N Diagnostics, LLC has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M. Holtzman is on the scientific advisory board of Denali and consults for Genentech and Idorsia. G.A.P. is on the scientific advisory boards of MeiraGTx, which develops gene therapies for neurodegenerative disorders including AD, and of Amicus Therapeutics and ProClara Biosciences. All other authors declare no competing interests.